辛伐他汀联合阿司匹林对糖尿病肾脏微血管病变患者脂代谢和炎性反应的影响及安全性分析

Analysis of the effect of Simvastatin combined with Aspirin on lipid metabolism and inflammatory response in patients with diabetic renal microangiopathy and its safety

目的探讨辛伐他汀联合阿司匹林对糖尿病肾脏微血管病变患者脂代谢和炎性反应的影响及其安全性。方法选取2016年2月至2017年10月本院收治的110例糖尿病肾脏微血管病变患者为研究对象,按照随机数表法将入选患者分为观察组和对照组,每组各55例。观察组患者采用辛伐他汀联合阿司匹林治疗,对照组患者仅采用阿司匹林单药治疗,比较两组患者治疗前后血脂水平、炎性因子水平及不良反应发生率。结果治疗后,两组患者总胆固醇(total cholesterol,TC)、甘油三酯(triglyceride,TG)、低密度脂蛋白胆固醇(low density lipoprotein-cholesterol,LDL-C)、P-选择素、肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)、高敏C反应蛋白(high sensitivity C-reactive protein,hs-CRP)、白介素-1β(interleukin-1β,IL-1β)、细胞间黏附分子(intercelluar adhesion molecule,ICAM)水平均显著低于本组治疗前(P_均<0.05),高密度脂蛋白胆固醇(high density lipoprotein-cholesterol,HDL-C)水平均显著高于本组治疗前(P_均<0.05);且观察组患者TC、TG、LDL-C、P-选择素、TNF-α、hs-CRP、IL-1β、ICAM水平均显著低于同期对照组(P_均<0.05),HDL-C水平显著高于同期对照组(P <0.05)。观察组患者不良反应总发生率显著低于对照组(P <0.05)。结论辛伐他汀联合阿司匹林能够显著降低糖尿病肾脏微血管病变患者血脂和炎性因子水平,且安全性较好。

Objective To investigate the effect of Simvastatin combined with Aspirin on lipid metabolism and inflammatory response in patients with diabetic renal microangiopathy and its safety.Method 110 patients with diabetic renal microangiopathy treated in our hospital from February 2016 to October 2017 were selected as the subjects of the study,according to the method of random number table,the selected patients were divided into observation group(n=55)and control group(n=55).Patients in observation group were treated with Simvastatin combined with Aspirin,while patients in control group were treated with Aspirin only,he levels of blood lipid,inflammatory factors and the incidence of adverse reactions were compared between the two groups before and after treatment.Result After treatment,the levels of total cholesterol(TC),triglyceride(TG),low density lipoprotein-cholesterol(LDL-C),P-selectin,tumor necrosis factor-α(TNF-α),high sensitivity C-reactive protein(hs-CRP),interleukin-1β(IL-1β),intercelluar adhesion molecule(ICAM)in the two groups were significantly lower than those before treatment(Pall<0.05),the level of high density lipoproteincholesterol(HDL-C)was significantly higher than that before treatment(Pall<0.05),the levels of TC,TG,LDL-C,P-selectin,TNF-α,hs-CRP,IL-1β,ICAM in observation group were significantly lower than those in control group(Pall<0.05),the level of HDL-C was significantly higher than that of control group(P<0.05).Conclusion Simvastatin combined with Aspirin can significantly reduce the levels of blood lipid and inflammatory factors in patients with diabetic renal microangiopathy,and the safety is good.